SELLAS reports 41% death‑risk reduction and median overall survival gain in Phase 3 AML vaccine trial
SELLAS Life Sciences announced that its galinpepimut‑S (GPS) vaccine met the primary overall‑survival endpoint in the Phase 3 REGAL trial for acute myeloid leukemia. The vaccine cut the risk of death by 41% (hazard ratio 0.59) and extended median overall survival to 24.0 months versus 14.7 months with best‑available treatment. The company will meet the FDA to discuss an accelerated filing and plans a Biologics License Application in the first half of 2027.
Why it matters
The company said the results will be presented to the FDA to pursue an accelerated approval pathway, which could bring a new therapy to a high‑need AML population and drive further upside for shareholders.
Key facts
- 1The REGAL trial showed a 41% reduction in risk of death (hazard ratio 0.59). finanznachrichten.de
- 2Median overall survival was 24.0 months for GPS‑treated patients versus 14.7 months for the control arm. finanznachrichten.de
- 3The primary endpoint was met with a two‑sided p‑value of 0.035. finanznachrichten.de
- 4SELLAS plans to discuss an accelerated FDA filing and submit a Biologics License Application in the first half of 2027. finanznachrichten.de
- 5Shares surged more than 220% in pre‑market trading after the announcement. invezz.com
- 6The stock traded at $20.20, up 170.42%, on volume of over 72 million shares. investorideas.com
Summary written by AlphAI AI Desk from 20 of 26 sources. Not investment advice. Figures are as stated by the linked sources.